Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Strategy Inc. (MSTR) vs Viatris Inc (VTRS) Price & Performance

Strategy Inc.Trade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Strategy Inc. vs Viatris Inc — how do they compare? Strategy Inc. trades at $155.29 (market cap $61.16B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Strategy Inc. is far larger — about 3× Viatris Inc's market cap, and Viatris Inc pays a 2.74% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 112 Days and Viatris Inc for 57 Days on average.

MSTRVTRS
Market Cap
$61.16B$20.12B
Volume
21,318,5617,543,511
Sector
TechnologyHealth
52-Week High
$320.29$18.27
52-Week Low
$82.31$9.74
Typical Hold Time
112 Days57 Days
Enterprise Value
$79.92B$32.24B
Dividend Yield
—2.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Strategy Inc.

MSTR stock trades at $151.47, down 7.95% over 24 hours, with a bullish technical signal from moving averages. The company reported a net loss of $3.85 billion for 2025 on revenue of $477.23 million, with a deeply negative net income margin of -6,102.96%. Despite severe profitability challenges, analyst consensus remains optimistic with a $252 price target, and recent news highlights significant stock volatility tied to Bitcoin market movements.

The outlook is bifurcated: strong analyst buy ratings and a high price target suggest upside potential, but fundamental weaknesses including persistent losses and negative cash flow from operations pose substantial risks. Investment appeal hinges on speculative sentiment rather than current financial health, with volatility expected to continue.

Viatris Inc

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.

The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MSTR
54% Buy46% Sell
Avg holding period · 112 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Strategy Inc.

MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web

Read more on MSTR →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →